New Analyses of Daytime Acid Control with Esomeprazole 20 mg
Philip O. Katz(Cornell University), Peter J. Kahrilas(Northwestern University), John Dent(Royal Adelaide Hospital), Tore Lind(Skaraborg Hospital), David A. Johnson(University of Chicago), Barry Traxler(AstraZeneca (United States)), Kerstin Röhss(AstraZeneca (Sweden))
Cited by 0
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
|Circulation|2008|845
Healing and relapse of severe peptic esophagitis after treatment with omeprazole
|Gastroenterology|1988|786